PTGS2 and non-small cell lung carcinoma: COX-2 inhibitors for treating NSCLC did not increase the risk of thrombosis or embolism (RR = 1.23; 95% CI: 0.71, 2.14) and the risk of cardiac ischemia (RR = 2.35; 95% CI: 0.61, 9.0).